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Abstract
Background: Fetal growth restriction (FGR) is a serious obstetric condition for which there is currently no treatment.
The EVERREST Prospective Study has been designed to characterise the natural history of pregnancies affected by severe
early onset FGR and establish a well phenotyped bio-bank. The findings will provide up-to-date information for clinicians
and patients and inform the design and conduct of the EVERREST Clinical Trial: a phase I/IIa trial to assess the safety and
efficacy of maternal vascular endothelial growth factor (VEGF) gene therapy in severe early onset FGR. Data and samples
from the EVERREST Prospective Study will be used to identify ultrasound and/or biochemical markers of prognosis in
pregnancies with an estimated fetal weight (EFW) <3rd centile between 20+0 and 26+6 weeks of gestation.
Methods: This is a 6 year European multicentre prospective cohort study, recruiting women with a singleton pregnancy
where the EFW is <3rd centile for gestational age and <600 g at 20+0 to 26+6 weeks of gestation. Detailed
data are collected on: maternal history; antenatal, peripartum, and postnatal maternal complications; health
economic impact; psychological impact; neonatal condition, progress and complications; and infant growth
and neurodevelopment to 2 years of corrected age in surviving infants. Standardised longitudinal ultrasound
measurements are performed, including: fetal biometry; uterine artery, umbilical artery, middle cerebral artery,
and ductus venosus Doppler velocimetry; and uterine artery and umbilical vein volume blood flow. Samples
of maternal blood and urine, amniotic fluid (if amniocentesis performed), placenta, umbilical cord blood, and
placental bed (if caesarean delivery performed) are collected for bio-banking. An initial analysis of maternal blood
samples at enrolment is planned to identify biochemical markers that are predictors for fetal or neonatal death.
Discussion: The findings of the EVERREST Prospective Study will support the development of a novel therapy for severe
early onset FGR by describing in detail the natural history of the disease and by identifying women whose pregnancies
have the poorest outcomes, in whom a therapy might be most advantageous. The findings will also enable better
counselling of couples with affected pregnancies, and provide a valuable resource for future research into the causes of FGR.
Trial registration: NCT02097667 registered 31st October 2013.
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Background
Fetal growth restriction (FGR) is a serious condition af-
fecting about 8% of all pregnancies and contributing to
30% of stillbirths [1]. As yet there is no therapy that im-
proves fetal growth in utero, thus current management is
to deliver the fetus before intrauterine death or irrevers-
ible organ damage occurs [2]. This is particularly challen-
ging in early onset FGR, where delivery adds additional
risks to the baby from extremely preterm birth, with its
own attendant short and long-term complications [3–5].
Furthermore FGR may be detected when the estimated
fetal weight (EFW) is below 500 g, a situation considered
by many to be non-viable. FGR is most commonly due to
three principal factors: a) maternal diseases such as infec-
tions; b) fetal chromosomal, genetic, or structural anomal-
ies; and, most often, c) placental insufficiency. Placental
insufficiency manifests as inadequate uteroplacental blood
flow on ultrasound scan and maternal vascular malperfu-
sion (MVM) on placental histology [6].
We are currently developing a treatment for FGR
caused by placental insufficiency [orphan designation
EU/3/14/1415], using maternal adenovirus gene therapy
to increase expression of vascular endothelial growth
factor (VEGF) protein in the uterine arteries. VEGF is
secreted by the placenta, induces vasodilatation, and me-
diates vasculogenesis and angiogenesis [7, 8]. In FGR,
however, maternal serum levels of VEGF are significantly
lower than in normal pregnancy [9, 10]. Previous studies
in normal sheep pregnancy show that administering
adenovirus VEGF gene therapy (Ad.VEGF) into the ma-
ternal uterine arteries increases uterine artery blood vol-
ume flow long-term, causes nitric oxide release and
relaxes the vessels [11–13]. Further studies in sheep and
guinea pig models of FGR have shown that administer-
ing Ad.VEGF gene therapy into the maternal uterine ar-
teries safely increases fetal growth [14, 15].
The EVERREST Consortium plans to carry out a phase
I/IIa trial to assess the safety and efficacy of maternal uter-
ine artery injection of Ad.VEGF in women with pregnan-
cies affected by severe early onset FGR. This will be called
the EVERREST Clinical Trial. For the first-in-woman trial
of maternal gene therapy the eligibility criteria will be de-
signed to identify severely affected pregnancies, where the
balance of risk and potential benefit is most favourable.
These pregnancies will naturally have high rates of mater-
nal, fetal, and neonatal complications. The safety and effi-
cacy of the intervention in the trial pregnancies will need
to be compared with data from a cohort of similar severely
affected pregnancies that do not undergo intervention.
Several prospective cohort studies have investigated
the outcomes of pregnancies where the fetus was found
to be small in mid-pregnancy [16–21]. Recent outcome
data have also been provided by the Trial of Umbilical
and Fetal Flow in Europe (TRUFFLE), a randomised
controlled trial comparing different indications for deliv-
ery in pregnancies diagnosed with severe FGR from
26 weeks of gestation onwards [22, 23]. However, none
of these studies includes the level of detailed maternal,
fetal, and infant outcome data required to properly as-
sess safety in the EVERREST Clinical Trial [24]. A de-
tailed study of the natural history of pregnancies affected
by severe early onset FGR is therefore required.
The EVERREST Prospective Study will clinically and
biochemically characterise a cohort of pregnancies af-
fected by severe early onset FGR across the four Euro-
pean centres that will be taking part in the EVERREST
Clinical Trial. A database will be created containing in-
formation about antenatal investigations, maternal com-
plications, fetal outcome and neonatal progress. This
will be linked to a bio-bank containing samples includ-
ing maternal blood and umbilical cord blood as well as
tissue from the placenta, placental bed, and the myome-
trium. These samples will be used to investigate the nat-
ural history and biological mechanisms which underlie
severe early onset FGR and, in conjunction with the
database, will be used to investigate potential biomarkers
for fetal and neonatal outcome.
Methods
Aims
1. To characterise the natural history of pregnancies
affected by severe early onset FGR in order to:
a. Provide up-to-date knowledge for clinicians and
future patients.
b. Interpret the safety of maternal growth factor
gene therapy in a future clinical trial.
2. To establish a bio-bank of well phenotyped samples
that can be used to investigate the biological mecha-
nisms underlying severe early onset FGR.
3. To identify ultrasound and/or biochemical
markers of prognosis in pregnancies with an EFW
<3rd centile between 20+0 and 26+6 weeks of
gestation.
Design
This is a 6-year European multicentre prospective co-
hort study. The design and publication of this protocol
has been performed in line with the ‘strengthening the
reporting of observational studies in epidemiology’
(STROBE) guidelines [25, 26].
Study population
Inclusion criteria
 Live singleton fetus.
 Estimated fetal weight <600 g and <3rd centile for
gestational age as defined by local criteria.
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 Gestational age at diagnosis 20+0 to 26+6 weeks of
gestation, based on ultrasound and/or last menstrual
period.
 Informed consent given by the participant and
signed consent form completed.
Exclusion criteria
 Multiple pregnancy.
 Maternal age under 18 years.
 Known abnormal karyotype at enrolment.
 Known major fetal structural abnormality at
enrolment defined as a lethal, incurable or curable
severe abnormality with a high risk of residual
handicap [27].
 Indication for immediate delivery.
 Women who lack the capacity to give informed
consent.
 Any medical or psychiatric condition which
compromises the woman’s ability to participate.
 Maternal HIV or hepatitis B or C infection.
 Premature preterm rupture of membranes before
enrolment.
Study setting
Participants are recruited from University College Hospital
London, University Medical Centre Hamburg-Eppendorf,
Maternal-Fetal Unit Hospital Clinic Barcelona, and the
Skane University Hospital, Lund. All four sites are tertiary
referral centres for their surrounding area, performing
12,000 to 20,000 fetal ultrasound scans per year.
Study procedures
The study timeline is shown in Fig. 1.
Data collection
In order to fully characterise this cohort, an extensive
data set is collected for each participant. This includes,
but is not limited to, the majority of the optimal data
set recommended by the Global Pregnancy CoLabora-
tory (COLAB) [28]. At enrolment maternal demo-
graphic, medical, obstetric, social, and family history
are collected, as well as paternal demographic and fam-
ily history and details of previously fathered pregnan-
cies. Data are collected on the current pregnancy,
including the results of ultrasound scans before and
after enrolment, screening tests, invasive tests, and tests
for maternal infection.
Data are collected about maternal antenatal, perinatal,
and postnatal complications. Perinatal data are collected
about the delivery, any maternal medication, the condi-
tion of the newborn and any need for resuscitation. For
liveborn infants, data are collected at 4, 24 h, and 7 days
of life as well as at discharge from the Neonatal Unit, if
applicable. This includes data on cardiovascular, meta-
bolic and respiratory status, growth, feeding, cranial
ultrasound findings, retinopathy screening, and any
medical or surgical complications. Surviving infants and
children undergo neurodevelopmental follow-up until
2 years of age (corrected for prematurity, Table 1).
Detailed health economic data are collected at ap-
proximately 6 weeks and 6 months post-delivery, in-
cluding maternal and infant health service use and
personal financial costs.
Fig. 1 Participant timelines for the EVERREST Prospective Study
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All data are entered onto a central MACRO database
using the participant’s unique Participation Identification
Number. This password protected database is stored on
servers based at University College London, which are
protected by thorough electronic and physical security
measures. Within the database electronic Case Report
Forms include internal data checks for validity and
consistency, and regular data checks are performed by
the EVERREST Study Manager.
Ultrasound measurements
The timing of ultrasound scans is determined clinically,
with fetal biometry recorded on the database no more
than once a week. All ultrasound measurements are per-
formed according to a Standard Operating Procedure
(SOP, see Additional file 1). Fetal biometry includes head
and abdominal circumference, both measured using an
ellipse, and femur length, all measured according to the
guidelines of the International Society of Ultrasound in
Obstetrics and Gynecology (ISUOG) [29]. Doppler ultra-
sound measurements are performed with the Doppler
gate across the whole width of the vessel, the angle of
insonation below 30°, with measurements taken from
three or more consecutive uniform waveforms. Pulsati-
lity index (PI) is recorded for the umbilical artery (from
a free-floating portion), the middle cerebral artery, and
the ductus venosus. End-diastolic flow in the umbilical
artery and the a wave of the ductus venosus are charac-
terised as positive, absent, or reversed. Uterine artery
volume blood flow is measured after the participant has
been resting for at least 20 min. Each uterine artery is
visualised using power Doppler, using the minimum
power setting needed to delineate the vessel walls. The
vessel diameter is measured perpendicular to the vessel
during systole, between the outer aspects of the lumen,
and the waveform is recorded to measure time averaged
mean (TAMEAN), PI, and to define the presence or ab-
sence of notching as described [30]. Umbilical vein vol-
ume blood flow is recorded from an intra-abdominal
section of the umbilical vein, with the TAMEAN re-
corded with the angle of insonation as close as possible
to 0° and the vessel diameter measured perpendicular
to the lumen, between the inner aspects of the vessel
walls [31].
Because neither uterine artery volume flow nor umbil-
ical vein volume flow are routinely performed in any of
the centres, a validation system has been established for
these measurements. Within each site the local ultra-
sound lead reviews images taken by all members of staff
performing EVERREST study measurements, both when
they first scan a study patient and then annually there-
after. These images are scored according to predefined
criteria, with further training and review if images are
unsatisfactory. Once a year the local ultrasound lead
must submit three sets of assessed images, along with
the score they gave to each, to the study ultrasound lead
for review.
Sample collection
Sample collection and processing procedures are per-
formed according to the laboratory manual and SOPs.
Maternal blood is collected at enrolment and delivery
for plasma, citrated plasma, serum, RNA (PAXgene®
tube), full blood count, renal and liver function, and
lactate dehydrogenase. At enrolment maternal whole
blood is stored for DNA. Maternal urine is collected
at enrolment and delivery with aliquots of whole
urine, urine centrifuged at slow and fast speeds, and
the pellet from centrifugation. Any excess amniotic
fluid from amniocentesis is also stored. At delivery
umbilical cord blood is collected for arterial and ven-
ous gases, blood spot cards, plasma, and serum (as-
suming sufficient volume can be collected). Placental
samples are collected from two areas of the placental
parenchyma, each midway between the cord insertion
and the margin in areas free from macroscopic in-
farcts. From each area full thickness samples are col-
lected for histological analysis, and samples from the
placental villous parenchyma (maternal and fetal sur-
faces removed) snap frozen and/or stored in RNALa-
ter®. For women undergoing delivery by caesarean
section a placental bed biopsy is also collected and
processed for histological analysis.
Table 1 EVERREST Prospective Study infant neurodevelopmental follow-up plan
Age (corrected for prematurity) 3 months 6 months 12 months 24 months
Growth and health X X X X
Prechtl video assessment X
Amiel Tison neurological assessment, hearing, vision, and general assessment of development X X
Hammersmith neuroassessment X X
Bayley III X X
Gross Motor Function Classification System (GMFCS) X
Manual Ability Classification System (MACS) X
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Participant experience
A recent amendment in the UK has extended the study to
explore the impact on women of experiencing a pregnancy
complicated by early onset FGR and of participating in re-
search during pregnancy. At enrolment women are asked
to complete the state section of the State-Trait Anxiety In-
ventory (STAI) [32]. This is repeated at 6–12 weeks post-
natally, along with the Edinburgh Postnatal Depression
Scale (EPDS) [33] and the 2008 version of the Perinatal
Posttraumatic Stress Disorder Questionnaire (PPQ) [34].
In addition, all study participants who have consented to
ongoing contact with the study have been invited to take
part in a semi-structured qualitative interview sub-study
and to complete a modified version of the Reactions to Re-
search Participation Questionnaire (RRPQ) [35].
Sample analyses
Three initial analysis strategies are planned for maternal
blood samples taken at study enrolment:
1. Targeted angiogenic and anti-angiogenic markers:
soluble FMS-like tyrosine kinase 1 (sFlt-1) and
placental growth factor (PlGF) will be measured
using the Roche Elecsys® automated electrochemi-
luminescence assay, VEGF-A, VEGF-D, soluble
VEGF receptor-2, soluble endoglin, and neuropilin 1
will be measured using R&D Systems enzyme-linked
immunosorbent assays (ELISAs).
2. Semi-targeted vascular markers: 92 serum analytes
implicated in cardiovascular disease will be
measured on the Olink ProSEEK platform, using
DNA primer-tagged antibody pairs in a proximity
extension assay to provide very sensitive (1 uL serum)
and specific measurements.
3. Non-targeted proteomic analysis: a mass
spectrometry-based serum profiling approach will
be employed for the discovery of potential new bio-
markers. Serum samples will be pooled into good and
poor outcome groups and subjected to an established
proteomic profiling workflow involving immunodeple-
tion of the 12 most abundant serum proteins, tryptic
digestion, 6-plex tandem mass tagging (TMT),
and two-dimensional liquid chromatography (high
and low pH reversed-phase) linked to quantitative
tandem mass spectrometry. Candidate selection
from the combined dataset will be based on
standard statistical tests of fold-change, MS data
quality and known function. Selected candidates
will be further verified in the individual discovery
samples using commercial ELISAs.
Outcomes
The first aim of the study, characterising the natural his-
tory of severe early onset FGR, will involve multiple
descriptive outcomes. The second aim, establishing a
bio-bank, involves the creation of a resource for ongoing
research with numerous potential endpoints. For the
third aim, identifying prognostic markers, there will be
two endpoints:
Primary Endpoint: Poor outcome, defined as fetal or
neonatal death, including death in utero and within the
first 28 days of life.
Secondary Endpoint: Time from enrolment to the end
of pregnancy, defined as either diagnosis of stillbirth or
delivery.
Statistical analysis
Characterising the natural history of severe early onset
FGR (Aim 1) will involve descriptive statistical methods,
including means for numerical variables and proportions
for binary or categorical variables. An initial analysis is
planned for the first 65 study participants to help refine
the inclusion criteria for the EVERREST Clinical Trial.
The association between individual factors and out-
come will be analysed using t tests and chi-squared tests,
and non-parametric tests used if required (Mann–Whit-
ney U tests and Fisher’s exact tests). Logistic regression
modelling will be used to investigate whether individual
and combinations of factors can be used to estimate
poor outcome (primary endpoint). These factors include
ultrasound findings, levels and ratios of angiogenic factors,
and potential markers identified through the semi-
targeted and proteomic approaches. Due to the relatively
small sample size, a forward selection algorithm will be
employed, and it is likely that each model will only sustain
a maximum of two or three independent variables. Models
will be tested for goodness of fit and discrimination using
leave-one out cross validation and bootstrapping.
Survival analysis, including Cox proportional hazards
regression, will be used to investigate the predictive value
of individual and combined factors for the secondary out-
come measure of time until the end of pregnancy.
An a priori sample size calculation is not provided, as
there is currently no reliable data on expected means
and standard deviations of candidate markers within
such a cohort, and no data on whether and how these
would differ by outcome. Within our current sample of
65, with 5 withdrawals and 18 poor outcomes, there is a
ratio of good to poor outcomes of 2.33. This sample will
give an 80% power to detect a standardised effect size of
1.0 to a significance level of 0.05 [36]. The potential for
type 1 error, given the multiple comparisons, or type 2
error, given the small sample size, will be borne in mind
when interpreting the study results.
Discussion
Developing novel maternal and fetal therapies raises
many challenges [37]. By characterising the natural
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history of severe early onset FGR the EVERREST Pro-
spective study will make it possible to assess the safety
and efficacy of maternal Ad.VEGF gene therapy in an
early phase clinical trial. The identification of prognostic
markers may also help refine the eligibility criteria for
later phase clinical trials, improving the chance of suc-
cessful translation into the clinic. The natural history
data will also be available for comparison with other
novel therapies that may be in development [2].
Establishing this study within the context of a pan-
European collaboration has provided both challenges
and benefits. Development of the study protocol and
SOPs has highlighted the variation in practice that exists
between clinical fetal medicine units. Routine clinical
practice in the four study sites uses different methods of
measuring fetal biometry, different formulae for EFW,
and different reference ranges for EFW and Doppler
measurements. These have been harmonised for the
EVERREST Prospective Study, providing us with the
basis to move forwards for the EVERREST Clinical Trial.
Through establishing the ultrasound validation system
we have also addressed the potential for variation in
practice in a multicentre study.
Defining the eligibility criteria was complicated by the
considerable heterogeneity in the way the term FGR is
used and defined. An EFW below the third centile has
been chosen as the inclusion criteria for the EVERREST
Prospective Study in order to identify the smallest fe-
tuses, at the highest risk of adverse perinatal outcome
[17]. This is consistent with the recent Delphi consensus
on the definition of early placental FGR [38]. An upper
limit of 600 g and 26+6 weeks of gestation was included
because Consortium members considered that above
these parameters, delivery would be a more appropriate
option than participation in the EVERREST Clinical
Trial. The inclusion criteria do not include any Doppler
ultrasound measurements, meaning that there is the po-
tential for inclusion of pregnancies where the fetus is
constitutionally small. This was a deliberate decision in
order to avoid initially excluding women who subse-
quently manifested signs of placental insufficiency. More
restrictive eligibility criteria are planned for the EVERR-
EST Clinical Trial, and outcomes will be compared with
women from prospective study who would have met
these more stringent criteria.
An important feature of the EVERREST Prospective
Study is the detailed maternal, fetal, and infant data that
are being collected. The outcomes to be recorded were
initially developed by pooling variables collected in other
obstetric and neonatal studies across the four centres.
Shortly after the launch of the study COLAB published
their minimum and optimum data sets for studies on
pre-eclampsia [28]. Many of these variables are applic-
able to all studies in pregnancy, and given the overlap
between pre-eclampsia and FGR they are particularly
relevant to the EVERREST Prospective Study. We there-
fore expanded the data collection to include the majority
of their optimal data set. COLAB will shortly be launch-
ing a database incorporating their recommended data
sets, which will be a valuable resource for future preg-
nancy studies.
The EVERREST Prospective Study has been designed
to support the development and conduct of the EVERR-
EST Clinical Trial, but we believe that its findings will
have wider applications. By providing outcome data and
prognostic markers for a severe early onset subset of
FGR, this study is likely to improve future patient coun-
selling and guide clinician’s management. The bio-bank
of comprehensively phenotyped samples will also sup-
port future research into the biological mechanisms
underlying FGR, and hopefully identify novel targets for
future therapies.
Additional file
Additional file 1: EVERREST Standard Operating Procedure for
performing ultrasound examinations. (PDF 1019 kb)
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